Clinical Trial

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Study acronym: MARGARET
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-12-23; most recent amendment 2026-02-28.
Trial Details
NCT Number NCT04683250
Lead Sponsor Taiho Pharmaceutical Co., Ltd.
Collaborators: Linical Co., Ltd.
Conditions RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Enrollment 244 participants
Start Date 2020-12-16
Primary Completion 2030-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-03